Comparative Pharmacology
Head-to-head clinical analysis: COXANTO versus IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COXANTO versus IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE.
COXANTO vs IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of soluble epoxide hydrolase (sEH), increasing levels of epoxyeicosatrienoic acids (EETs), which have vasodilatory, anti-inflammatory, and antifibrotic effects.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. Phenylephrine is a selective alpha-1 adrenergic receptor agonist, causing vasoconstriction.
1 g intravenous every 6 hours.
1 tablet (ibuprofen 200 mg/phenylephrine HCl 10 mg) orally every 4-6 hours as needed, not to exceed 6 tablets per 24 hours.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours (prolonged to 24-30 hours in moderate-to-severe renal impairment, requiring dose adjustment)
Ibuprofen: 2-4 hours (prolonged in overdose or hepatic impairment). Phenylephrine: 2-3 hours (clinical activity may persist longer due to vasoconstrictive effects).
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Ibuprofen: Renal elimination of metabolites (90%) and unchanged drug (1-10%); biliary/fecal excretion minor. Phenylephrine: Renal elimination (80-85% as inactive metabolites, 2-3% unchanged); biliary/fecal negligible.
Category C
Category D/X
NSAID
NSAID